In addition, in vivo studies suggest that decreased miR-19a-3p expression could be associated with increased of cardiac hypertrophy by phosphodiesterase 5A (PDE5A) and myocyte enhancer factor 2 (MEF2) regulation [27,28]. This evidence concerns the gene PDE5A and cardiac hypertrophy.